Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 010

Next Previous
X
Search
Drug Profile

CB 010

Alternative Names: Anti-CD19 CAR-T cell therapy - Caribou Biosciences; Anti-CD19 chimeric antigen receptor T cell therapy - Caribou Biosciences; Anti-CD19-CAR-T cells - Caribou Biosciences; CB-010

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caribou Biosciences
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 31 May 2024 Pharmacodynamics, efficacy and adverse events data from the phase I ANTLER trial in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 24 Apr 2024 CB 010 is still in phase-I development for Non-Hodgkin's-lymphoma (In the elderly, Second-line therapy or greater, In adults) in USA (Parenteral) (NCT04637763)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Second-line therapy or greater, In adults) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top